Drugs and Biomarkers
Test results interpretation for chemotherapeutic drugs
Interpretation of the results of the tests in the molecular profiling panel is informed by published clinical research studies that demonstrated an association of candidate biomarkers with response to drug treatment. Biomarkers correlated with response to chemotherapeutic agents commonly employed in ovarian cancer treatment are listed below in the Table. Included here are some of the markers that are comprised in the Clearity Tumor Molecular Profile; others will be incorporated into the profiling panel in the future. These markers were identified following a comprehensive literature review that surveyed published clinical research studies for correlations of the expression of tumor protein/mRNA or genomic mutations with response to drug treatment (or progression-free and overall survival following chemotherapy). Only biomarkers that have reproducibly significant associations with clinical responses to the indicated chemotherapy are included in this table (see Methods more details). To learn more about each drug and biomarker, or to view the literature support for each biomarker- drug response association, please click on the drug class of interest in the table or on the links in the right hand panel.
| List of Therapeutic Options and Associated Response Biomarkers* | ||||
|---|---|---|---|---|
| Drug Class | Drug | Sensitivity | Resistance | Cancer |
| Platinum | Carboplatin Cisplatin | BRCA1 mutation p21 | ERCC1 BRCA1 Bcl-xL Bcl-2 MT | Ovarian |
| Taxanes | Paclitaxel Docetaxel | BRCA1 | TUBB3 PGP Survivin ESR1 | Ovarian Breast |
| Nab-paclitaxel | SPARC | Head & Neck | ||
| Nucleoside Analogs | Gemcitabine | ENT1 DCK HuR | RRM1 RRM2 | Pancreatic Ovarian Lung |
| Topo I Inhibitors | Topotecan Irinotecan | TOP1 | Ovarian Colon |
|
| Topo II Inhibitors | Doxorubicin Etoposide | TOP2A | PGP | Ovarian |
| Fluoropyrimidines | 5-FU | TS | Colon, Gastric | |
| Capecitabine | TP | DPD EGFR | Colon, Lung, Breast | |
| Anti-folates | Pemetrexed | TS | Lung, Mesothelioma | |
*Response prediction markers for each drug class were identified by searching for relevant clinical research reports in the PubMed database. Click here for more detailed methods. Correlation (i.e., sensitivity or resistance) is indicated for high marker expression. Evidence for cancer type(s) other than ovarian is provided for the indicated biomarkers when no or limited clinical evidence for ovarian cancer exists. This literature survey was supported in part by the California Ovarian Cancer Awareness Program.
